Pendahuluan
Halaman ini memberikan analisis komprehensif tentang sejarah perdagangan orang dalam yang diketahui dari Patrick G Enright. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Adalah ilegal bagi orang dalam untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik yang tidak dipublikasikan. Ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan kepada SEC melalui Formulir 4. Terlepas dari pembatasan ini, penelitian akademis menunjukkan bahwa orang dalam - secara umum - cenderung mengungguli pasar di perusahaan mereka sendiri.
Rata-rata Profitabilitas Perdagangan
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari semua pembelian pasar terbuka yang dilakukan oleh orang dalam dalam tiga tahun terakhir. Untuk menghitung ini, kami memeriksa setiap pembelian pasar terbuka yang tidak direncanakan yang dilakukan oleh orang dalam, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata dari perdagangan tersebut selama 3, 6, dan 12 bulan, dengan merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami merata-ratakan semua metrik kinerja untuk menghitung metrik kinerja untuk orang dalam. Daftar ini hanya mencakup orang dalam yang telah melakukan setidaknya tiga perdagangan dalam dua tahun terakhir.
Jika profitabilitas perdagangan orang dalam ini adalah "N/A", maka orang dalam tersebut belum melakukan pembelian di pasar terbuka dalam tiga tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang andal.
Frekuensi Pembaruan: Setiap Hari
Lihat daftar pedagang dalam perusahaan yang paling menguntungkan.
Perusahaan dengan Posisi Orang Dalam yang Dilaporkan
Pengajuan SEC menunjukkan bahwa Patrick G Enright telah melaporkan kepemilikan atau perdagangan di perusahaan-perusahaan berikut:
Keamanan | Judul | Kepemilikan Terakhir yang Dilaporkan |
---|---|---|
US:JAZZ / Jazz Pharmaceuticals plc | Director | 26,379 |
US:VERA / Vera Therapeutics, Inc. | Director | 3,596,593 |
Director | 1,710,589 | |
Director | 774,530 | |
US:LXEO / Lexeo Therapeutics, Inc. | 10% Owner | 2,567,100 |
US:APTX / Aptinyx Inc. | Director | 40,000 |
US:SRRA / Sierra Oncology Inc | 10% Owner | 8,015 |
US:INZY / Inozyme Pharma, Inc. | 10% Owner | 4,174,379 |
US:RPID / Rapid Micro Biosystems, Inc. | 10% Owner | 129,032 |
US:TALS / Talaris Therapeutics Inc | 10% Owner | 0 |
US:EAR / Eargo, Inc. | 10% Owner | 5,012 |
US:ETNB / 89bio, Inc. | 10% Owner | 891 |
Director | 0 | |
US:MTEM / Molecular Templates, Inc. | 10% Owner | 0 |
US:VERO / Venus Concept Inc. | 10% Owner | 7,332,238 |
US:AXNX / Axonics, Inc. | 10% Owner | 0 |
US:TCDA / Tricida Inc | 10% Owner | 0 |
US:COLL / Collegium Pharmaceutical, Inc. | 10% Owner | 45,620 |
US:KALA / KALA BIO, Inc. | 10% Owner | 0 |
US:CORT / Corcept Therapeutics Incorporated | Director | 114,675 |
US:ESPR / Esperion Therapeutics, Inc. | Director | 8,000 |
Cara Membaca Grafik
Grafik berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka yang tidak direncanakan yang dilakukan oleh Patrick G Enright. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham digambarkan sebagai perubahan persentase kumulatif dalam harga saham. Misalnya, jika perdagangan orang dalam dilakukan pada 1 Januari 2019, grafik akan menunjukkan perubahan persentase harian sekuritas hingga saat ini. Jika harga saham naik dari $10 menjadi $15 selama periode ini, perubahan persentase kumulatif dalam harga saham akan menjadi 50%. Perubahan harga dari $10 menjadi $20 akan menjadi 100%, dan perubahan harga dari $10 menjadi $5 akan menjadi -50%.
Pada akhirnya, kita mencoba menentukan seberapa erat korelasi perdagangan orang dalam dengan pengembalian berlebih (positif atau negatif) pada harga saham untuk melihat apakah orang dalam tersebut mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi orang dalam. Pertimbangkan situasi di mana orang dalam melakukan hal ini. Dalam situasi ini, kita akan mengharapkan (a) pengembalian positif setelah pembelian, atau (b) pengembalian negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, menunjukkan pengembalian positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, menunjukkan pengembalian negatif setelah setiap transaksi penjualan.
Namun, ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam tren kenaikan non-siklikal selama bertahun-tahun, maka kita akan mengharapkan semua plot pasca-pembelian memiliki kemiringan ke atas. Demikian pula, penurunan non-siklikal selama bertahun-tahun akan menghasilkan plot pasca-perdagangan dengan kemiringan ke bawah. Tak satu pun dari grafik ini akan menunjukkan aktivitas perdagangan orang dalam.
Indikator terkuat adalah situasi di mana harga saham sangat siklikal, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat menunjukkan adanya orang dalam yang mengatur waktu perdagangan untuk keuntungan finansial mereka.
Pembelian Orang Dalam COLL / Collegium Pharmaceutical, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam COLL / Collegium Pharmaceutical, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CORT / Corcept Therapeutics Incorporated - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CORT / Corcept Therapeutics Incorporated - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ESPR / Esperion Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ESPR / Esperion Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ETNB / 89bio, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ETNB / 89bio, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam KALA / KALA BIO, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2017-07-25 | KALA | Longitude Capital Partners II, LLC | 215,000 | 15.0000 | 4,300 | 750.0000 | 3,225,000 | 51 | 1326.5 | 2,478,950 | 76.87 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam KALA / KALA BIO, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam LXEO / Lexeo Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-07 | LXEO | Longitude Capital Partners IV, LLC | 454,545 | 11.0000 | 454,545 | 11.0000 | 4,999,995 | 219 | 18.7600 | 3,527,269 | 70.55 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam LXEO / Lexeo Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam RPID / Rapid Micro Biosystems, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-07-19 | RPID | Longitude Capital Partners II, LLC | 150,000 | 20.0000 | 150,000 | 20.0000 | 3,000,000 | 17 | 24.8 | 720,000 | 24.00 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam RPID / Rapid Micro Biosystems, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam TRML / Tourmaline Bio, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-05-11 | TALS | Longitude Capital Partners III, LLC | 235,000 | 17.0000 | 235,000 | 17.0000 | 3,995,000 | 27 | 18.61 | 378,350 | 9.47 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam TRML / Tourmaline Bio, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam VERA / Vera Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam VERA / Vera Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam VERO / Venus Concept Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam VERO / Venus Concept Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di COLL / Collegium Pharmaceutical, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Sejarah Perdagangan Orang Dalam
Tabel ini menunjukkan daftar lengkap transaksi orang dalam yang dilakukan oleh Patrick G Enright sebagaimana diungkapkan kepada Komisi Bursa Efek (Securities Exchange Commission/SEC).
Tanggal File | Tanggal Transaksi | Formulir | Ticker | Keamanan | Kode | Saham | Sisa Saham | Persen Ubah |
Bagikan Harga |
Tran Nilai |
Sisa Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
F - Taxes | -1,805 | 26,379 | -6.40 | 111.25 | -200,805 | 2,934,640 | |
2025-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 3,507 | 28,184 | 14.21 | ||||
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 27,071 | 3,596,593 | 0.76 | 22.35 | 605,083 | 80,389,968 | |
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 13,536 | 1,797,619 | 0.76 | 22.35 | 302,553 | 40,179,841 | |
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 139,595 | 3,569,522 | 4.07 | 20.87 | 2,913,110 | 74,489,856 | |
2025-06-25 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 69,798 | 1,784,083 | 4.07 | 20.87 | 1,456,566 | 37,230,779 | |
2024-09-27 |
|
4 | BIOA |
BioAge Labs, Inc.
Common Stock |
P - Purchase | 400,000 | 1,710,589 | 30.52 | 18.00 | 7,200,000 | 30,790,602 | |
2024-09-27 |
|
4 | BIOA |
BioAge Labs, Inc.
Common Stock |
C - Conversion | 1,310,589 | 1,310,589 | |||||
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
P - Purchase | 440,000 | 774,530 | 131.53 | 17.00 | 7,480,000 | 13,167,010 | |
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
C - Conversion | 334,530 | 334,530 | |||||
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
C - Conversion | 1,003,592 | 1,727,404 | 138.65 | ||||
2024-09-16 |
|
4 | ZBIO |
Zenas BioPharma, Inc.
Common Stock |
C - Conversion | 723,812 | 723,812 | |||||
2024-08-06 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 3,731 | 24,677 | 17.81 | ||||
2023-11-09 |
|
4 | LXEO |
Lexeo Therapeutics, Inc.
Common Stock |
P - Purchase | 454,545 | 2,567,100 | 21.52 | 11.00 | 4,999,995 | 28,238,100 | |
2023-11-09 |
|
4 | LXEO |
Lexeo Therapeutics, Inc.
Common Stock |
C - Conversion | 319,126 | 2,112,555 | 17.79 | ||||
2023-11-09 |
|
4 | LXEO |
Lexeo Therapeutics, Inc.
Common Stock |
C - Conversion | 1,793,429 | 1,793,429 | |||||
2023-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,241 | 20,946 | -5.59 | 138.16 | -171,455 | 2,893,868 | |
2023-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 3,075 | 22,187 | 16.09 | ||||
2023-02-08 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 1,714,285 | 1,714,285 | 7.00 | 11,999,995 | 11,999,995 | ||
2022-11-25 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,000 | 0 | -100.00 | 152.88 | -305,751 | ||
2022-11-25 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,069 | 19,112 | -9.77 | 149.90 | -310,149 | 2,864,942 | |
2022-11-25 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,905 | 21,181 | -12.06 | 149.18 | -433,364 | 3,159,752 | |
2022-08-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,089 | 24,086 | -4.33 | 152.33 | -165,883 | 3,668,934 | |
2022-08-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,561 | 25,175 | 11.32 | ||||
2022-05-31 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40,000 | 40,000 | |||||
2022-05-26 |
|
4 | VERA |
Vera Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 9,925 | 9,925 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 840 | 8,015 | 11.71 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 252 | 2,404 | 11.71 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 588 | 5,611 | 11.71 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 7,175 | 7,175 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 2,152 | 2,152 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | 5,023 | 5,023 | |||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | -1,964,771 | 0 | -100.00 | ||||
2022-04-29 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
J - Other | -175,000 | 0 | -100.00 | ||||
2022-04-21 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
P - Purchase | 1,355,000 | 4,174,379 | 48.06 | 3.69 | 4,999,950 | 15,403,459 | |
2022-04-05 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 333,333 | 3,429,927 | 10.76 | 15.00 | 4,999,995 | 51,448,905 | |
2022-02-02 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
P - Purchase | 175,000 | 175,000 | 27.00 | 4,725,000 | 4,725,000 | ||
2022-01-27 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series B Warrants |
X - Other | -1,477,125 | 0 | -100.00 | 13.20 | -19,498,050 | ||
2022-01-27 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
X - Other | 487,451 | 1,964,771 | 33.00 | 13.20 | 6,434,353 | 25,934,977 | |
2021-08-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,000 | 2,000 | 137.75 | 275,500 | 275,500 | ||
2021-08-02 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,246 | 22,614 | 11.03 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Common Stock Warrant |
C - Conversion | 129,032 | 129,032 | |||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series B1 Warrant |
C - Conversion | -645,160 | 0 | -100.00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Common Stock Warrant |
C - Conversion | 500,000 | 500,000 | |||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series A1 Warrant |
C - Conversion | -2,500,000 | 0 | -100.00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series C1 Preferred Stock |
C - Conversion | -2,291,665 | 0 | -100.00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series B1 Preferred Stock |
C - Conversion | -5,654,529 | 0 | -100.00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Series A1 Preferred Stock |
C - Conversion | -8,774,007 | 0 | -100.00 | ||||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock |
P - Purchase | 150,000 | 150,000 | 20.00 | 3,000,000 | 3,000,000 | ||
2021-07-20 |
|
4 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock |
C - Conversion | 3,344,038 | 3,407,952 | 5,232.09 | ||||
2021-07-14 | 3 | RPID |
RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock |
63,914 | ||||||||
2021-06-01 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40,000 | 40,000 | |||||
2021-05-18 |
|
4 | VERA |
Vera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -2,187,504 | 0 | -100.00 | ||||
2021-05-18 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
P - Purchase | 909,090 | 3,096,594 | 41.56 | 11.00 | 9,999,990 | 34,062,534 | |
2021-05-18 |
|
4 | VERA |
Vera Therapeutics, Inc.
Class A Common Stock |
C - Conversion | 2,187,504 | 2,187,504 | |||||
2021-05-17 |
|
4 | VERA |
Vera Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 9,925 | 9,925 | |||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -406,338 | 0 | -100.00 | ||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Series A-1 Preferred Stock |
C - Conversion | -1,271,027 | 0 | -100.00 | ||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1,308,410 | 0 | -100.00 | ||||
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Common Stock |
P - Purchase | 235,000 | 3,220,775 | 7.87 | 17.00 | 3,995,000 | 54,753,175 | |
2021-05-11 |
|
4 | TALS |
Talaris Therapeutics, Inc.
Common Stock |
C - Conversion | 2,985,775 | 2,985,775 | |||||
2021-04-15 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
J - Other | 5,012 | 5,012 | |||||
2021-04-15 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
J - Other | X | -1,000,000 | 2,918,691 | -25.52 | |||
2021-01-05 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 8,149 | 8,149 | 2.22 | 18,123 | 18,123 | ||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | 891 | 891 | |||||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | 2,080 | 2,080 | |||||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | 2,973 | 2,973 | |||||
2020-11-18 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
J - Other | -850,000 | 1,750,877 | -32.68 | ||||
2020-11-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,623 | 20,368 | -7.38 | 147.61 | -239,575 | 3,006,565 |
2020-11-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -5,083 | 21,991 | -18.77 | 147.00 | -747,217 | 3,232,747 |
2020-11-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -3,223 | 27,074 | -10.64 | 145.81 | -469,946 | 3,947,665 |
2020-11-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Phantom Stock |
M - Exercise | -9,929 | 0 | -100.00 | ||||
2020-11-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | 9,929 | 30,297 | 48.75 | ||||
2020-10-22 |
|
4 | EAR |
Eargo, Inc.
Series E Preferred Stock |
C - Conversion | -3,685,358 | 0 | -100.00 | ||||
2020-10-22 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
P - Purchase | 233,333 | 3,918,691 | 6.33 | 18.00 | 4,199,994 | 70,536,438 | |
2020-10-22 |
|
4 | EAR |
Eargo, Inc.
Common Stock |
C - Conversion | 3,685,358 | 3,685,358 | |||||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -15,398 | 0 | -100.00 | 17.39 | -267,771 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -11,432 | 0 | -100.00 | 14.60 | -166,907 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -7,500 | 0 | -100.00 | 1.71 | -12,825 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -17,500 | 0 | -100.00 | 16.24 | -284,200 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -19,755 | 0 | -100.00 | 19.10 | -377,320 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -52,421 | 0 | -100.00 | 28.21 | -1,478,796 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
D - Sale to Issuer | -65,849 | 0 | -100.00 | 34.36 | -2,262,572 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
D - Sale to Issuer | -7,840 | 0 | -100.00 | 34.50 | -270,480 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
U - Other | -91,697 | 0 | -100.00 | 34.50 | -3,163,546 | ||
2020-10-14 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
U - Other | -70,561 | 0 | -100.00 | 34.50 | -2,434,354 | ||
2020-10-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 8,379 | 8,379 | 2.16 | 18,124 | 18,124 | ||
2020-09-23 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | 91,697 | 91,697 | |||||
2020-09-23 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -6,113,134 | 0 | -100.00 | ||||
2020-09-01 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
S - Sale | -1,049 | 0 | -100.00 | 10.75 | -11,273 | ||
2020-09-01 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
S - Sale | -2,447 | 0 | -100.00 | 10.75 | -26,296 | ||
2020-08-10 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 6,765 | 6,765 | |||||
2020-08-10 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,705 | 20,368 | 15.31 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -1,398,600 | 0 | -100.00 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -15,000,000 | 0 | -100.00 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
P - Purchase | 625,000 | 2,819,379 | 28.48 | 16.00 | 10,000,000 | 45,110,064 | |
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
C - Conversion | 187,154 | 2,194,379 | 9.32 | ||||
2020-07-28 |
|
4 | INZY |
Inozyme Pharma, Inc.
Common Stock |
C - Conversion | 2,007,225 | 2,007,225 | |||||
2020-07-14 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
P - Purchase | 109,090 | 2,600,877 | 4.38 | 27.50 | 2,999,975 | 71,524,118 | |
2020-07-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5,436 | 5,436 | 2.68 | 14,552 | 14,552 | ||
2020-05-29 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,398 | 15,398 | |||||
2020-05-29 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
S - Sale | 7,840 | 78,401 | 11.11 | ||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | 1,049 | 1,049 | |||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | 2,447 | 2,447 | |||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | 3,495 | 3,495 | |||||
2020-05-28 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
J - Other | -1,000,000 | 3,199,035 | -23.81 | ||||
2020-05-22 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40,000 | 40,000 | |||||
2020-04-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 8,573 | 8,573 | 1.36 | 11,625 | 11,625 | ||
2020-03-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 16,213 | 70,561 | 29.83 | 11.06 | 179,345 | 780,532 | |
2020-03-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 8,787 | 54,348 | 19.29 | 11.50 | 101,050 | 625,002 | |
2020-03-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 100,000 | 6,113,134 | 1.66 | 11.40 | 1,139,650 | 69,668,332 | |
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series A Convertible Voting Preferred Stock |
C - Conversion | -19,500 | 0 | -100.00 | ||||
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
C - Conversion | 1,477,320 | 1,477,320 | |||||
2020-01-14 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
P - Purchase | 166,667 | 3,356,746 | 5.22 | 3.00 | 500,001 | 10,070,238 | |
2020-01-14 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
P - Purchase | 95,000 | 95,000 | 3.00 | 285,000 | 285,000 | ||
2020-01-03 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5,427 | 5,427 | 2.14 | 11,625 | 11,625 | ||
2019-12-05 |
|
4/A | MTEM |
Molecular Templates, Inc.
Common Stock |
P - Purchase | 937,500 | 4,199,035 | 28.74 | 8.00 | 7,500,000 | 33,592,280 | |
2019-11-27 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
P - Purchase | 937,000 | 4,198,535 | 28.73 | 8.00 | 7,496,000 | 33,588,280 | |
2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Series A Preferred Stock |
C - Conversion | -11,916,667 | 0 | -100.00 | ||||
2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
C - Conversion | 1,916,787 | 2,491,787 | 333.35 | ||||
2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
P - Purchase | 575,000 | 575,000 | 16.00 | 9,200,000 | 9,200,000 | ||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7,332,238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7,332,238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7,332,238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7,332,238 | ||||||||
2019-11-07 | 3 | VERO |
Venus Concept Inc.
Common Stock |
7,332,238 | ||||||||
2019-10-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5,582 | 5,582 | 2.08 | 11,622 | 11,622 | ||
2019-09-19 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 12,500 | 45,561 | 37.81 | 22.34 | 279,216 | 1,017,710 | |
2019-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -726 | 17,663 | -3.95 | 135.65 | -98,481 | 2,395,967 | |
2019-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 4,805 | 4,805 | |||||
2019-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,920 | 18,389 | 11.66 | ||||
2019-07-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 5,866 | 5,866 | 1.98 | 11,626 | 11,626 | ||
2019-05-28 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 11,432 | 11,432 | |||||
2019-05-28 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 6,442 | 33,061 | 24.20 | ||||
2019-05-17 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 40,000 | 40,000 | |||||
2019-04-02 |
|
4 | APTX |
Aptinyx Inc.
Stock Option (Right to Buy) |
A - Award | 4,793 | 4,793 | 2.42 | 11,623 | 11,623 | ||
2018-11-02 |
|
4 | AXNX |
Axonics Modulation Technologies, Inc.
Series C Preferred Stock |
C - Conversion | -2,000,000 | 0 | -100.00 | ||||
2018-11-02 |
|
4 | AXNX |
Axonics Modulation Technologies, Inc.
Common Stock |
P - Purchase | 533,333 | 2,933,333 | 22.22 | 15.00 | 7,999,995 | 43,999,995 | |
2018-11-02 |
|
4 | AXNX |
Axonics Modulation Technologies, Inc.
Common Stock |
C - Conversion | 2,400,000 | 2,400,000 | |||||
2018-09-25 |
|
4 | MTEM |
Molecular Templates, Inc.
Common Stock |
P - Purchase | 365,000 | 3,261,535 | 12.60 | 5.50 | 2,007,500 | 17,938,442 | |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -3,415 | 0 | -100.00 | |||
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -3,415 | 0 | -100.00 | |||
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -3,300 | 0 | -100.00 | |||
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,000 | 16,469 | -5.72 | 169.69 | -169,694 | 2,794,690 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -7,086 | 17,469 | -28.86 | 168.86 | -1,196,565 | 2,949,873 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -2,044 | 24,555 | -7.68 | 167.96 | -343,305 | 4,124,199 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 3,300 | 26,599 | 14.16 | 135.44 | 446,952 | 3,602,569 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 3,415 | 23,299 | 17.17 | 138.08 | 471,543 | 3,217,126 |
2018-09-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 3,415 | 19,884 | 20.74 | 143.66 | 490,599 | 2,856,535 |
2018-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,365 | 16,469 | -7.65 | 175.13 | -239,057 | 2,884,272 | |
2018-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 3,735 | 3,735 | |||||
2018-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,495 | 17,834 | 9.15 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -1,817,447 | 0 | -100.00 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -9,677,419 | 0 | -100.00 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
P - Purchase | 131,579 | 3,019,734 | 4.56 | 19.00 | 2,500,001 | 57,374,946 | |
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
C - Conversion | 456,644 | 2,888,155 | 18.78 | ||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
C - Conversion | 2,431,511 | 2,431,511 | |||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Series B Convertible Preferred Stock |
C - Conversion | -21,946,301 | 0 | -100.00 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -33,022,786 | 0 | -100.00 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -28,895,188 | 0 | -100.00 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
P - Purchase | 150,000 | 3,190,079 | 4.93 | 16.00 | 2,400,000 | 51,041,264 | |
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
C - Conversion | 795,553 | 3,040,079 | 35.44 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
C - Conversion | 1,197,076 | 2,244,526 | 114.28 | ||||
2018-06-26 |
|
4 | APTX |
Aptinyx Inc.
Common Stock |
C - Conversion | 1,047,450 | 1,047,450 | |||||
2018-05-24 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 7,500 | 7,500 | |||||
2018-05-24 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 3,750 | 26,619 | 16.40 | ||||
2018-02-26 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock |
P - Purchase | 15,593 | 22,869 | 214.31 | 32.00 | 498,976 | 731,808 | |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | -4,500 | 0 | -100.00 | |||
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-employee director stock option |
M - Exercise | X | -4,500 | 0 | -100.00 | |||
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -2,842 | 16,339 | -14.82 | 140.50 | -399,294 | 2,295,592 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -5,358 | 19,181 | -21.83 | 139.56 | -747,771 | 2,676,931 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -800 | 24,539 | -3.16 | 138.14 | -110,516 | 3,389,940 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 4,500 | 25,339 | 21.59 | 81.76 | 367,920 | 2,071,717 |
2017-12-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
M - Exercise | X | 4,500 | 20,839 | 27.54 | 46.83 | 210,735 | 975,890 |
2017-12-12 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
S - Sale | -19,650 | 45,620 | -30.11 | 17.34 | -340,731 | 791,051 | |
2017-12-12 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
S - Sale | -980,350 | 2,276,222 | -30.10 | 17.34 | -16,999,269 | 39,469,689 | |
2017-11-21 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -352 | 1,365 | -20.50 | 133.19 | -46,883 | 181,804 |
2017-08-28 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -351 | 1,717 | -16.97 | 148.40 | -52,088 | 254,803 |
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3 | 2,068 | -0.14 | 144.13 | -432 | 298,062 | |
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -659 | 2,071 | -24.14 | 142.36 | -93,815 | 294,828 | |
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 3,415 | 3,415 | |||||
2017-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,365 | 2,730 | 100.00 | ||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5,793,070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5,793,070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5,793,070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5,793,070 | ||||||||
2017-08-07 | 3 | MTEM |
Molecular Templates, Inc.
Common Stock |
5,793,070 | ||||||||
2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -10,707,985 | 0 | -100.00 | ||||
2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 215,000 | 2,270,946 | 10.46 | 15.00 | 3,225,000 | 34,064,190 | |
2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 2,055,946 | 2,055,946 | |||||
2017-05-30 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 17,500 | 17,500 | |||||
2017-03-20 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -5,305 | 114,675 | -4.42 | 9.94 | -52,722 | 1,139,652 | |
2017-03-20 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -264,650 | 5,721,372 | -4.42 | 9.94 | -2,630,515 | 56,868,149 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -5,483 | 139,630 | -3.78 | 10.24 | -56,131 | 1,429,420 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -273,537 | 6,966,372 | -3.78 | 10.24 | -2,800,636 | 71,325,896 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -5,895 | 145,113 | -3.90 | 10.01 | -59,002 | 1,452,422 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -294,105 | 7,239,909 | -3.90 | 10.01 | -2,943,668 | 72,463,525 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -412 | 151,008 | -0.27 | 11.13 | -4,585 | 1,680,583 | |
2017-03-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -20,568 | 7,534,014 | -0.27 | 11.13 | -228,905 | 83,847,549 | |
2017-03-10 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -14,737 | 151,420 | -8.87 | 9.75 | -143,686 | 1,476,345 | |
2017-03-10 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -735,263 | 7,554,582 | -8.87 | 9.75 | -7,168,814 | 73,657,174 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -19,650 | 166,157 | -10.58 | 9.05 | -177,832 | 1,503,721 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -980,350 | 8,289,845 | -10.58 | 9.05 | -8,872,168 | 75,023,097 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -29,475 | 185,807 | -13.69 | 8.65 | -254,959 | 1,607,231 | |
2017-02-27 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1,470,525 | 9,270,195 | -13.69 | 8.65 | -12,720,041 | 80,187,187 | |
2016-12-14 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
J - Other | 204,210 | 204,210 | |||||
2016-12-06 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -677 | 1,365 | -33.15 | 101.80 | -68,919 | 138,957 |
2016-12-01 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | 7,276 | 7,276 | |||||
2016-12-01 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -1,500,000 | 6,013,134 | -19.97 | ||||
2016-11-30 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
J - Other | -58,950 | 121,153 | -32.73 | ||||
2016-11-30 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
J - Other | -2,941,050 | 10,834,849 | -21.35 | ||||
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -290 | 180,103 | -0.16 | 9.39 | -2,722 | 1,690,609 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -14,451 | 13,775,899 | -0.10 | 9.39 | -135,650 | 129,312,986 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -248 | 180,393 | -0.14 | 9.30 | -2,307 | 1,678,340 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -12,352 | 13,790,350 | -0.09 | 9.30 | -114,921 | 128,302,658 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -189 | 180,641 | -0.10 | 9.33 | -1,763 | 1,685,326 | |
2016-11-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -9,411 | 13,802,702 | -0.07 | 9.33 | -87,802 | 128,775,069 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -2,327 | 180,830 | -1.27 | 9.39 | -21,841 | 1,697,270 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -116,058 | 13,812,113 | -0.83 | 9.39 | -1,089,320 | 129,640,493 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1,976 | 183,157 | -1.07 | 9.47 | -18,720 | 1,735,156 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -98,586 | 13,928,171 | -0.70 | 9.47 | -933,964 | 131,949,921 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -6,389 | 185,133 | -3.34 | 9.64 | -61,612 | 1,785,312 | |
2016-11-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -318,764 | 14,026,757 | -2.22 | 9.64 | -3,073,969 | 135,265,628 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -342 | 191,522 | -0.18 | 9.51 | -3,252 | 1,821,125 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -17,052 | 14,345,521 | -0.12 | 9.51 | -162,142 | 136,407,256 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -3,094 | 191,864 | -1.59 | 9.55 | -29,558 | 1,832,954 | |
2016-11-17 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -154,359 | 14,362,573 | -1.06 | 9.55 | -1,474,653 | 137,211,405 | |
2016-08-17 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -633 | 2,042 | -23.66 | 136.45 | -86,373 | 278,631 | |
2016-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Non-Qualified Stock Option (right to buy) |
A - Award | 3,415 | 3,415 | |||||
2016-08-15 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,365 | 2,675 | 104.20 | ||||
2016-07-25 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Option (Right to Buy) |
A - Award | 30,000 | 30,000 | |||||
2016-05-27 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 19,755 | 19,755 | |||||
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45,440 | 7,513,134 | 0.61 | 14.15 | 642,817 | 106,284,550 | |
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 33,064 | 7,467,694 | 0.44 | 13.50 | 446,318 | 100,803,414 | |
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45,440 | 7,513,134 | 0.61 | 14.15 | 642,817 | 106,284,550 | |
2016-03-31 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 33,064 | 7,467,694 | 0.44 | 13.50 | 446,318 | 100,803,414 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -7 | 4,323 | -0.16 | 120.31 | -842 | 520,085 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 4,330 | -0.78 | 119.55 | -4,065 | 517,639 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -63 | 4,364 | -1.42 | 118.39 | -7,459 | 516,669 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -52 | 4,427 | -1.16 | 117.46 | -6,108 | 519,984 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 4,479 | -0.75 | 116.19 | -3,951 | 520,422 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6 | 4,513 | -0.13 | 114.43 | -687 | 516,408 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -393 | 215,677 | -0.18 | 120.32 | -47,288 | 25,951,227 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,666 | 216,070 | -0.77 | 119.55 | -199,165 | 25,830,542 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,159 | 217,736 | -1.43 | 118.40 | -374,013 | 25,779,050 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,594 | 220,895 | -1.16 | 117.46 | -304,692 | 25,946,415 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,698 | 223,489 | -0.75 | 116.20 | -197,304 | 25,968,930 | |
2016-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -294 | 225,187 | -0.13 | 114.43 | -33,641 | 25,767,405 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -24 | 4,519 | -0.53 | 139.24 | -3,342 | 629,220 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 4,543 | -1.24 | 138.37 | -7,887 | 628,594 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -116 | 4,600 | -2.46 | 137.71 | -15,974 | 633,454 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,214 | 225,481 | -0.54 | 139.24 | -169,043 | 31,397,034 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,843 | 226,695 | -1.24 | 138.36 | -393,371 | 31,366,563 | |
2016-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5,746 | 229,538 | -2.44 | 137.71 | -791,274 | 31,609,357 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -424 | 1,310 | -24.45 | 148.49 | -62,960 | 194,522 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 4,716 | -0.72 | 147.57 | -5,018 | 695,960 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -68 | 4,750 | -1.41 | 146.95 | -9,993 | 698,035 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -94 | 4,818 | -1.91 | 145.96 | -13,720 | 703,245 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,737 | 235,284 | -0.73 | 147.58 | -256,339 | 34,722,225 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,395 | 237,021 | -1.41 | 146.95 | -498,900 | 34,830,591 | |
2015-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4,672 | 240,416 | -1.91 | 145.96 | -681,940 | 35,091,889 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -18 | 4,912 | -0.37 | 137.96 | -2,483 | 677,663 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -36 | 4,930 | -0.72 | 137.16 | -4,938 | 676,174 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -32 | 4,966 | -0.64 | 135.85 | -4,347 | 674,626 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -62 | 4,998 | -1.23 | 134.76 | -8,355 | 673,548 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 5,060 | -0.67 | 133.95 | -4,554 | 677,766 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -8 | 5,094 | -0.16 | 132.70 | -1,062 | 675,974 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6 | 5,102 | -0.12 | 128.96 | -774 | 657,954 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -932 | 245,088 | -0.38 | 137.98 | -128,595 | 33,816,752 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,809 | 246,020 | -0.73 | 137.15 | -248,097 | 33,740,634 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,573 | 247,829 | -0.63 | 135.85 | -213,693 | 33,667,669 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,138 | 249,402 | -1.24 | 134.76 | -422,878 | 33,609,463 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,666 | 252,540 | -0.66 | 133.95 | -223,154 | 33,826,698 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -392 | 254,206 | -0.15 | 132.70 | -52,018 | 33,733,136 | |
2015-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -294 | 254,598 | -0.12 | 128.96 | -37,914 | 32,832,958 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1 | 5,108 | -0.02 | 137.81 | -138 | 703,933 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -34 | 5,109 | -0.66 | 136.60 | -4,645 | 697,910 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -10 | 5,143 | -0.19 | 135.73 | -1,357 | 698,039 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -25 | 5,153 | -0.48 | 134.32 | -3,358 | 692,137 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -83 | 5,178 | -1.58 | 132.94 | -11,034 | 688,358 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -43 | 5,261 | -0.81 | 132.26 | -5,687 | 695,799 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -99 | 254,892 | -0.04 | 137.81 | -13,643 | 35,126,667 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,695 | 254,991 | -0.66 | 136.60 | -231,540 | 34,832,230 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -490 | 256,686 | -0.19 | 135.73 | -66,506 | 34,838,964 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,225 | 257,176 | -0.47 | 134.32 | -164,539 | 34,543,160 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4,193 | 258,401 | -1.60 | 132.94 | -557,414 | 34,351,622 | |
2015-10-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,102 | 262,594 | -0.79 | 132.26 | -278,000 | 34,729,369 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -37 | 5,304 | -0.69 | 168.33 | -6,228 | 892,798 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -21 | 5,341 | -0.39 | 167.32 | -3,514 | 893,639 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -24 | 5,362 | -0.45 | 166.36 | -3,993 | 892,013 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 5,386 | -1.05 | 165.26 | -9,420 | 890,074 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 5,443 | -1.04 | 164.50 | -9,377 | 895,390 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,857 | 264,696 | -0.70 | 168.34 | -312,602 | 44,558,210 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,081 | 266,553 | -0.40 | 167.33 | -180,882 | 44,601,967 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,169 | 267,634 | -0.43 | 166.36 | -194,472 | 44,522,843 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,846 | 268,803 | -1.05 | 165.27 | -470,347 | 44,423,970 | |
2015-09-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,851 | 271,649 | -1.04 | 164.51 | -469,018 | 44,688,977 | |
2015-08-31 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -425 | 1,734 | -19.69 | 167.87 | -71,345 | 291,087 | |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -21 | 5,500 | -0.38 | 183.75 | -3,859 | 1,010,625 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -23 | 5,521 | -0.41 | 182.69 | -4,202 | 1,008,631 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -148 | 5,544 | -2.60 | 181.71 | -26,893 | 1,007,400 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -4 | 5,692 | -0.07 | 180.05 | -720 | 1,024,845 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,069 | 274,500 | -0.39 | 183.77 | -196,450 | 50,444,865 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,177 | 275,569 | -0.43 | 182.68 | -215,014 | 50,340,945 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -7,362 | 276,746 | -2.59 | 181.71 | -1,337,749 | 50,287,516 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -196 | 284,108 | -0.07 | 180.05 | -35,290 | 51,153,645 |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4 | 2,159 | -0.18 | 183.36 | -733 | 395,874 | |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -797 | 2,163 | -26.93 | 179.98 | -143,444 | 389,297 | |
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Nonstatutory Stock Option (right to buy) |
A - Award | 3,415 | 3,415 | |||||
2015-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,310 | 2,960 | 79.39 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3,248,600 | 0 | -100.00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3,873,530 | 0 | -100.00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 312,500 | 7,434,630 | 4.39 | 16.00 | 5,000,000 | 118,954,080 | |
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3,248,600 | 7,122,130 | 83.87 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3,873,530 | 3,873,530 | |||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3,248,600 | 0 | -100.00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3,873,530 | 0 | -100.00 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 312,500 | 7,434,630 | 4.39 | 16.00 | 5,000,000 | 118,954,080 | |
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3,248,600 | 7,122,130 | 83.87 | ||||
2015-08-11 |
|
4 | AIMT |
Aimmune Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3,873,530 | 3,873,530 | |||||
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -10 | 5,696 | -0.18 | 178.59 | -1,786 | 1,017,254 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -60 | 5,706 | -1.04 | 177.74 | -10,665 | 1,014,196 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -105 | 5,766 | -1.79 | 176.86 | -18,570 | 1,019,761 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -22 | 5,871 | -0.37 | 175.81 | -3,868 | 1,032,165 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -543 | 284,304 | -0.19 | 178.59 | -96,977 | 50,775,017 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,986 | 284,847 | -1.04 | 177.74 | -530,727 | 50,628,222 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5,196 | 287,833 | -1.77 | 176.86 | -918,943 | 50,904,964 | |
2015-07-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,078 | 293,029 | -0.37 | 175.81 | -189,520 | 51,516,637 | |
2015-06-22 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Option (Right to Buy) |
A - Award | 30,000 | 30,000 | |||||
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -47 | 5,893 | -0.79 | 179.43 | -8,433 | 1,057,379 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -109 | 5,940 | -1.80 | 178.76 | -19,485 | 1,061,831 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -40 | 6,049 | -0.66 | 177.82 | -7,113 | 1,075,614 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,397 | 294,107 | -0.81 | 179.43 | -430,099 | 52,772,266 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5,447 | 296,504 | -1.80 | 178.76 | -973,685 | 53,001,928 | |
2015-06-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,960 | 301,951 | -0.64 | 177.82 | -348,521 | 53,691,961 | |
2015-05-18 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 8,000 | 8,000 | |||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series D Convertible Preferred Stock |
C - Conversion | -101,128 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series D Convertible Preferred Stock |
C - Conversion | -5,045,381 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series C Convertible Preferred Stock |
C - Conversion | -63,356 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series C Convertible Preferred Stock |
C - Conversion | -3,160,905 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series B Convertible Preferred Stock |
C - Conversion | -257,303 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Series B Convertible Preferred Stock |
C - Conversion | -12,837,935 | 0 | -100.00 | ||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
P - Purchase | 3,930 | 65,270 | 6.41 | 12.00 | 47,160 | 783,240 | |
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
C - Conversion | 61,340 | 61,340 | |||||
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
P - Purchase | 196,070 | 3,256,572 | 6.41 | 12.00 | 2,352,840 | 39,078,864 | |
2015-05-14 |
|
4 | COLL |
COLLEGIUM PHARMACEUTICAL, INC
Common Stock |
C - Conversion | 3,060,502 | 3,060,502 | |||||
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -60 | 6,089 | -0.98 | 176.63 | -10,598 | 1,075,517 | |
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -137 | 6,149 | -2.18 | 175.98 | -24,109 | 1,082,073 | |
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,022 | 303,911 | -0.98 | 176.64 | -533,800 | 53,682,201 | |
2015-05-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6,781 | 306,933 | -2.16 | 175.98 | -1,193,289 | 54,012,657 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -28 | 6,286 | -0.44 | 169.96 | -4,759 | 1,068,394 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -125 | 6,314 | -1.94 | 169.23 | -21,154 | 1,068,545 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -43 | 6,439 | -0.66 | 168.31 | -7,237 | 1,083,760 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,402 | 313,714 | -0.44 | 169.97 | -238,301 | 53,322,753 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6,275 | 315,116 | -1.95 | 169.24 | -1,061,958 | 53,329,097 | |
2015-04-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,127 | 321,391 | -0.66 | 168.32 | -358,008 | 54,095,280 | |
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -16,833 | 0 | -100.00 | ||||
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -839,811 | 0 | -100.00 | ||||
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 16,833 | 194,958 | 9.45 | 4.05 | 68,174 | 789,580 | |
2015-04-01 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 839,811 | 14,516,932 | 6.14 | 4.05 | 3,401,235 | 58,793,575 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -1,130,709 | 0 | -100.00 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -554,348 | 13,677,121 | -3.90 | 5.65 | -3,132,066 | 77,275,734 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 1,130,709 | 14,231,469 | 8.63 | 2.77 | 3,132,064 | 39,421,169 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -9,750 | 0 | -100.00 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -486,443 | 0 | -100.00 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrant (Right to Buy) |
X - Other | -634,516 | 1,130,709 | -35.95 | ||||
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -4,617 | 178,125 | -2.53 | 5.85 | -27,009 | 1,042,031 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 9,750 | 182,742 | 5.64 | 2.77 | 27,008 | 506,195 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -230,333 | 13,100,760 | -1.73 | 5.85 | -1,347,448 | 76,639,446 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 486,443 | 13,331,093 | 3.79 | 2.77 | 1,347,447 | 36,927,128 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -300,447 | 12,844,650 | -2.29 | 5.85 | -1,757,615 | 75,141,202 | |
2015-03-24 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 634,516 | 13,145,097 | 5.07 | 2.77 | 1,757,609 | 36,411,919 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -123 | 18,361 | -0.67 | 116.05 | -14,275 | 2,130,849 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -44 | 18,484 | -0.24 | 114.15 | -5,022 | 2,109,862 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -3,907 | 18,528 | -17.41 | 113.92 | -445,080 | 2,110,682 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -67 | 22,435 | -0.30 | 111.06 | -7,441 | 2,491,618 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -5,684 | 22,502 | -20.17 | 110.01 | -625,279 | 2,475,375 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -6,077 | 916,035 | -0.66 | 116.05 | -705,254 | 106,308,610 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -2,156 | 922,112 | -0.23 | 114.15 | -246,097 | 105,254,751 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -194,988 | 924,268 | -17.42 | 113.92 | -22,212,701 | 105,291,039 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -3,353 | 1,119,256 | -0.30 | 111.06 | -372,381 | 124,303,452 | |
2015-03-23 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -283,601 | 1,122,609 | -20.17 | 110.01 | -31,198,067 | 123,494,736 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3 | 6,482 | -0.05 | 177.51 | -533 | 1,150,620 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -87 | 6,485 | -1.32 | 176.79 | -15,381 | 1,146,501 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -57 | 6,572 | -0.86 | 176.03 | -10,033 | 1,156,838 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -38 | 6,629 | -0.57 | 175.06 | -6,652 | 1,160,498 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -12 | 6,667 | -0.18 | 172.60 | -2,071 | 1,150,713 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -197 | 323,518 | -0.06 | 177.51 | -34,969 | 57,427,680 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4,302 | 323,715 | -1.31 | 176.79 | -760,560 | 57,230,319 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,854 | 328,017 | -0.86 | 176.02 | -502,374 | 57,738,996 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,862 | 330,871 | -0.56 | 175.06 | -325,969 | 57,923,535 | |
2015-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -588 | 332,733 | -0.18 | 172.60 | -101,488 | 57,429,150 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3 | 6,679 | -0.04 | 168.13 | -504 | 1,122,940 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -68 | 6,682 | -1.01 | 167.51 | -11,391 | 1,119,298 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -125 | 6,750 | -1.82 | 166.45 | -20,807 | 1,123,568 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -197 | 333,321 | -0.06 | 168.14 | -33,123 | 56,042,960 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,382 | 333,518 | -1.00 | 167.51 | -566,507 | 55,866,400 | |
2015-02-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -6,225 | 336,900 | -1.81 | 166.46 | -1,036,187 | 56,078,925 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -9 | 6,875 | -0.13 | 161.54 | -1,454 | 1,110,588 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -88 | 6,884 | -1.26 | 160.75 | -14,146 | 1,106,600 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -100 | 6,972 | -1.41 | 159.68 | -15,968 | 1,113,262 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -495 | 343,125 | -0.14 | 161.57 | -79,975 | 55,437,368 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4,348 | 343,620 | -1.25 | 160.75 | -698,938 | 55,236,709 | |
2015-01-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -4,960 | 347,968 | -1.41 | 159.68 | -792,002 | 55,562,765 | |
2014-12-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -300 | 1,650 | -15.38 | 172.53 | -51,759 | 284,674 | |
2014-12-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -650 | 1,950 | -25.00 | 171.67 | -111,588 | 334,765 | |
2014-12-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,393 | 2,600 | -34.89 | 170.32 | -237,256 | 442,832 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5 | 7,072 | -0.07 | 177.10 | -886 | 1,252,451 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -10 | 7,077 | -0.14 | 174.97 | -1,750 | 1,238,263 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -48 | 7,087 | -0.67 | 173.73 | -8,339 | 1,231,216 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -60 | 7,135 | -0.83 | 173.03 | -10,382 | 1,234,553 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -25 | 7,195 | -0.35 | 171.65 | -4,291 | 1,235,033 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -48 | 7,220 | -0.66 | 170.96 | -8,206 | 1,234,337 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -295 | 352,928 | -0.08 | 177.10 | -52,244 | 62,503,549 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -490 | 353,223 | -0.14 | 174.97 | -85,735 | 61,803,428 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,403 | 353,713 | -0.67 | 173.73 | -417,466 | 61,449,569 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,007 | 356,116 | -0.84 | 173.02 | -520,280 | 61,616,259 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,208 | 359,123 | -0.34 | 171.65 | -207,349 | 61,642,314 | |
2014-12-03 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,401 | 360,331 | -0.66 | 170.97 | -410,495 | 61,605,142 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -8 | 28,186 | -0.03 | 32.13 | -257 | 905,653 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -92 | 28,194 | -0.33 | 31.57 | -2,904 | 889,989 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -412 | 1,406,210 | -0.03 | 32.14 | -13,241 | 45,192,355 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -4,592 | 1,406,622 | -0.33 | 31.56 | -144,944 | 44,399,179 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -2,722 | 28,286 | -8.78 | 33.79 | -91,975 | 955,773 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -2,728 | 31,008 | -8.09 | 32.93 | -89,844 | 1,021,214 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -4,021 | 33,736 | -10.65 | 32.01 | -128,718 | 1,079,940 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -135,816 | 1,411,214 | -8.78 | 33.79 | -4,589,182 | 47,684,498 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -136,148 | 1,547,030 | -8.09 | 32.93 | -4,483,885 | 50,949,731 | |
2014-11-19 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -200,591 | 1,683,178 | -10.65 | 32.01 | -6,421,219 | 53,881,053 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -46 | 7,268 | -0.63 | 171.71 | -7,899 | 1,247,971 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -151 | 7,314 | -2.02 | 170.90 | -25,805 | 1,249,934 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,258 | 362,732 | -0.62 | 171.71 | -387,716 | 62,283,841 | |
2014-11-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -7,545 | 364,990 | -2.03 | 170.90 | -1,289,438 | 62,376,682 | |
2014-10-14 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -19 | 37,757 | -0.05 | 30.00 | -570 | 1,132,710 | |
2014-10-14 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -924 | 1,883,769 | -0.05 | 30.00 | -27,720 | 56,513,070 | |
2014-10-09 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -235 | 37,776 | -0.62 | 30.04 | -7,059 | 1,134,802 | |
2014-10-09 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
S - Sale | -11,692 | 1,884,693 | -0.62 | 30.04 | -351,230 | 56,616,555 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -43 | 7,465 | -0.57 | 161.57 | -6,947 | 1,206,085 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -104 | 7,508 | -1.37 | 160.65 | -16,708 | 1,206,165 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -49 | 7,612 | -0.64 | 159.47 | -7,814 | 1,213,914 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,157 | 372,535 | -0.58 | 161.57 | -348,516 | 60,192,082 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -5,197 | 374,692 | -1.37 | 160.65 | -834,911 | 60,195,169 | |
2014-10-08 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,450 | 379,889 | -0.64 | 159.48 | -390,738 | 60,586,559 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -38 | 7,661 | -0.49 | 163.88 | -6,227 | 1,255,464 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -159 | 7,699 | -2.02 | 162.71 | -25,871 | 1,252,690 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,909 | 382,339 | -0.50 | 163.89 | -312,865 | 62,661,386 | |
2014-09-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -7,894 | 384,248 | -2.01 | 162.71 | -1,284,424 | 62,520,569 | |
2014-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,087 | 3,993 | -21.40 | 133.15 | -144,734 | 531,668 | |
2014-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Nonstatutory Stock Option (right to buy) |
A - Award | 3,300 | 3,300 | |||||
2014-08-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1,650 | 5,080 | 48.10 | ||||
2014-05-16 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 5,000 | 5,000 | |||||
2014-05-12 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 30,000 | 30,000 | |||||
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1,699 | 172,992 | -0.97 | 4.07 | -6,918 | 704,389 | |
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -84,744 | 12,510,581 | -0.67 | 4.07 | -345,061 | 50,940,584 | |
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -3,214 | 174,691 | -1.81 | 4.12 | -13,256 | 720,513 | |
2014-05-05 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -160,343 | 12,595,325 | -1.26 | 4.12 | -661,335 | 51,949,418 | |
2014-04-03 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -4,912 | 177,905 | -2.69 | 4.28 | -21,035 | 761,843 | |
2014-04-03 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -245,088 | 12,755,668 | -1.89 | 4.28 | -1,049,540 | 54,623,597 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -205 | 182,817 | -0.11 | 4.00 | -820 | 731,268 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -10,225 | 13,000,756 | -0.08 | 4.00 | -40,900 | 52,003,024 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -3,303 | 183,022 | -1.77 | 4.00 | -13,214 | 732,216 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -164,800 | 13,010,981 | -1.25 | 4.00 | -659,315 | 52,053,032 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -1,404 | 186,325 | -0.75 | 4.01 | -5,630 | 747,126 | |
2014-03-07 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
S - Sale | -70,063 | 13,175,781 | -0.53 | 4.01 | -280,939 | 52,832,247 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,895 | 0 | -100.00 | 153.80 | -599,043 | ||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,166 | 3,895 | -23.04 | 150.45 | -175,429 | 586,017 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,700 | 5,061 | -42.23 | 149.42 | -552,855 | 756,216 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -2,700 | 8,761 | -23.56 | 148.55 | -401,088 | 1,301,456 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -300 | 11,461 | -2.55 | 147.87 | -44,360 | 1,694,700 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
X - Other | -18,624 | 0 | -100.00 | ||||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
X - Other | -929,243 | 0 | -100.00 | ||||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -8,731 | 7,858 | -52.63 | 150.50 | -1,314,016 | 1,182,629 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -435,588 | 392,142 | -52.62 | 150.50 | -65,555,994 | 59,017,371 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -559 | 16,589 | -3.26 | 159.03 | -88,897 | 2,638,127 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -28,070 | 827,730 | -3.28 | 159.03 | -4,463,927 | 131,632,578 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -423 | 17,148 | -2.41 | 159.91 | -67,642 | 2,742,121 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -20,977 | 855,800 | -2.39 | 159.91 | -3,354,449 | 136,851,663 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -180 | 17,571 | -1.01 | 160.77 | -28,939 | 2,824,944 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -8,866 | 876,777 | -1.00 | 160.76 | -1,425,330 | 140,953,827 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -787 | 17,751 | -4.25 | 161.93 | -127,442 | 2,874,492 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -39,241 | 885,643 | -4.24 | 161.93 | -6,354,448 | 143,415,625 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -71 | 18,538 | -0.38 | 162.94 | -11,569 | 3,020,574 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -3,645 | 924,884 | -0.39 | 162.94 | -593,906 | 150,698,102 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1 | 18,609 | -0.01 | 164.50 | -164 | 3,061,180 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -28 | 928,529 | 0.00 | 164.50 | -4,606 | 152,743,020 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -14 | 18,610 | -0.08 | 165.94 | -2,323 | 3,088,143 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -686 | 928,557 | -0.07 | 165.94 | -113,835 | 154,084,749 | |
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
X - Other | 18,624 | 18,624 | 4.00 | 74,496 | 74,496 | ||
2014-03-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
X - Other | 929,243 | 929,243 | 4.00 | 3,716,972 | 3,716,972 | ||
2013-08-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,070 | 3,430 | -23.78 | 81.86 | -87,590 | 280,780 | |
2013-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Nonstatutory Stock Option (right to buy) |
A - Award | 4,500 | 4,500 | |||||
2013-08-12 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,250 | 4,500 | 100.00 | ||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 21,471 | 21,471 | |||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -33,753 | 0 | -100.00 | ||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1,683,967 | 0 | -100.00 | ||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 4,258 | 38,011 | 12.62 | 14.00 | 59,612 | 532,154 | |
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 212,418 | 1,896,385 | 12.61 | 14.00 | 2,973,852 | 26,549,390 | |
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 33,753 | 33,753 | |||||
2013-07-01 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 1,683,967 | 1,683,967 | |||||
2013-05-21 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 30,000 | 30,000 | |||||
2013-03-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -15,720 | 15,422 | -50.48 | 58.28 | -916,162 | 898,794 | |
2013-03-07 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -784,280 | 768,670 | -50.50 | 58.28 | -45,707,838 | 44,798,088 | |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -921 | 31,142 | -2.87 | 58.13 | -53,536 | 1,810,228 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -46,451 | 1,552,950 | -2.90 | 58.13 | -2,700,085 | 90,269,256 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -4 | 32,063 | -0.01 | 59.04 | -236 | 1,893,000 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -375 | 32,067 | -1.16 | 58.41 | -21,905 | 1,873,110 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -196 | 1,599,401 | -0.01 | 59.04 | -11,572 | 94,428,635 |
2013-02-20 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -18,703 | 1,599,597 | -1.16 | 58.41 | -1,092,476 | 93,435,340 |
2013-01-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -456 | 32,442 | -1.39 | 56.72 | -25,865 | 1,840,159 |
2013-01-16 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -22,772 | 1,618,300 | -1.39 | 56.72 | -1,291,669 | 91,792,889 |
2013-01-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -31 | 32,898 | -0.09 | 56.54 | -1,753 | 1,860,033 |
2013-01-14 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,569 | 1,641,072 | -0.10 | 56.54 | -88,710 | 92,785,226 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -706 | 32,929 | -2.10 | 56.52 | -39,906 | 1,861,299 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -35,216 | 1,642,641 | -2.10 | 56.52 | -1,990,563 | 92,849,297 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -117 | 33,635 | -0.35 | 56.52 | -6,612 | 1,900,932 |
2013-01-11 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -5,783 | 1,677,857 | -0.34 | 56.52 | -326,834 | 94,826,437 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -72 | 33,752 | -0.21 | 59.34 | -4,273 | 2,002,877 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -1,228 | 33,824 | -3.50 | 58.59 | -71,946 | 1,981,681 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -3,667 | 1,683,640 | -0.22 | 59.34 | -217,607 | 99,910,565 |
2012-10-04 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | X | -61,683 | 1,687,307 | -3.53 | 58.59 | -3,613,884 | 98,855,943 |
2012-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Option (right to buy) |
A - Award | 4,500 | 4,500 | |||||
2012-08-13 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,250 | 2,250 | |||||
2012-06-15 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 30,000 | 30,000 | |||||
2012-04-02 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrants (Right to Buy) |
P - Purchase | 856,644 | 856,644 | 0.12 | 107,080 | 107,080 | ||
2012-04-02 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Warrants (Right to Buy) |
X - Other | -856,644 | 0 | -100.00 | 0.12 | -107,080 | ||
2012-04-02 |
|
4 | CORT |
CORCEPT THERAPEUTICS INC
Common Stock |
X - Other | 856,644 | 13,433,573 | 6.81 | 2.96 | 2,535,666 | 39,763,376 | |
2012-03-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -21,615 | 35,052 | -38.14 | 49.56 | -1,071,239 | 1,737,177 | |
2012-03-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -1,078,400 | 1,748,990 | -38.14 | 49.56 | -53,445,504 | 86,679,944 | |
2012-03-09 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
S - Sale | -49,985 | 0 | -100.00 | 49.56 | -2,477,257 | ||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
A - Award | 18,624 | 18,624 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
A - Award | 929,243 | 929,243 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Phantom Stock |
A - Award | 9,929 | 9,929 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 56,667 | 56,667 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 2,827,390 | 2,827,390 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 49,985 | 49,985 | |||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
D - Sale to Issuer | -18,624 | 0 | -100.00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Warrant (right to buy) |
D - Sale to Issuer | -929,243 | 0 | -100.00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Phantom Stock |
D - Sale to Issuer | -9,929 | 0 | -100.00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Common Stock |
D - Sale to Issuer | -56,667 | 0 | -100.00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Common Stock |
D - Sale to Issuer | -2,827,390 | 0 | -100.00 | ||||
2012-01-18 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Common Stock |
D - Sale to Issuer | -49,985 | 0 | -100.00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -12,500 | 0 | -100.00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -12,500 | 0 | -100.00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -10,000 | 0 | -100.00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Option (right to buy) |
M - Exercise | -30,000 | 0 | -100.00 | ||||
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -8,999 | 49,985 | -15.26 | 48.60 | -437,351 | 2,429,271 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12,500 | 58,984 | 26.89 | 34.99 | 437,375 | 2,063,850 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2,116 | 46,484 | -4.35 | 48.60 | -102,838 | 2,259,122 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12,500 | 48,600 | 34.63 | 8.23 | 102,875 | 399,978 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -1,302 | 36,100 | -3.48 | 48.60 | -63,277 | 1,754,460 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10,000 | 37,402 | 36.49 | 6.33 | 63,300 | 236,755 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2,598 | 27,402 | -8.66 | 48.60 | -126,263 | 1,331,737 | |
2012-01-13 |
|
4 | JAZZ |
JAZZ PHARMACEUTICALS INC
Common Stock |
M - Exercise | 30,000 | 30,000 | 4.21 | 126,300 | 126,300 |